Children with autism spectrum disorder often face gut troubles alongside core behavioral challenges. Many exhibit lower microbial diversity in their intestines than peers without the condition. Researchers have tested whether transferring healthy bacteria through fecal microbiota transplants could shift that balance. Early open-label studies delivered striking numbers. But questions linger about what holds up under stricter scrutiny.
In one trial from Arizona State University, 18 children received microbiota transfer therapy. The protocol combined antibiotics, a bowel cleanse, a stomach-acid suppressant and then repeated fecal transplants. At the two-year mark, gastrointestinal symptoms stayed 58% lower than starting levels on the Gastrointestinal Symptom Rating Scale. Autism-related symptoms dropped even further. The Childhood Autism Rating Scale score fell 47% from baseline. Before treatment 83% of participants rated severe. Afterward just 17% did. Some 44% scored below the cutoff for an autism diagnosis.
“The long-term benefits observed here two years after MTT stopped are very encouraging,” the authors wrote in Scientific Reports. They noted persistent rises in bacterial diversity and in beneficial groups such as Bifidobacterium and Prevotella. And the gains in adaptive behaviors outpaced what doctors usually see in this population.
But the trial carried clear limits. It lacked a placebo arm. Some families adjusted diets or medicines during follow-up. Critics point out that autism symptoms tend to stay stable without major intervention. So how much of the change traces directly to the transplant?
A newer approach skips the harsh prep. Japanese researchers tested a fecal microbial solution suspended in hydrogen nanobubble water. They gave 30 children weekly enemas for six weeks. No antibiotics. No cleansing. The method proved safe with zero adverse events reported. Social Responsiveness Scale scores fell 29% at 30 weeks and held steady a year later. In kids without gastrointestinal complaints the drop reached 45%. Gastrointestinal Symptom Rating Scale scores plunged 61% among those who had gut issues. Sensory problems eased. Anxiety and depression scores halved.
“This novel hydrogen nanobubble water–based FMT method was safe and effective, reducing both core and peripheral symptoms of ASD,” the team stated in Frontiers in Pediatrics. They highlighted increases in beneficial bacteria and short-chain fatty acids. The protocol used material from one carefully screened donor and far fewer bacteria than standard transplants. That simplicity could matter for wider use.
Other work adds nuance. A 2025 open-label controlled study of colonoscopic fecal transplants in 30 children found no significant difference on the Autism Diagnostic Observation Schedule at eight weeks. Yet parent-reported measures moved. The Childhood Autism Rating Scale improved markedly. Gastrointestinal scores got better. Some gains lasted to 18 months. The authors called their findings exploratory and stressed the need for larger blinded trials. The paper appeared in Medicina.
Experts remain split on the gut-brain story in autism. A Science article from late 2025 described much of the microbiome research as deeply flawed. Small trials without proper controls dominate the record. One recent placebo-controlled fecal transplant study found no difference between groups. Still, the authors acknowledged that some open studies report gains in both gut symptoms and behavior. They called for rigorous work.
The original refractor.io piece summarized these patterns well. It quoted Rosa Krajmalnik-Brown noting a strong connection between intestinal microbes and brain signals. Many autistic children with gut problems show worse behavioral symptoms. Fix the gut, behavior often follows. That observation echoes across datasets. Yet correlation does not prove causation. Diet, antibiotics, and other factors shape the microbiome too.
Regulatory doors stay narrow. The FDA has approved fecal microbiota transplants only for recurrent Clostridioides difficile infection. Autism applications stay experimental. Several trials appear on ClinicalTrials.gov. One evaluates emotional behavior alongside gut and autism symptoms. Another tests safety of endoscopic delivery. Chinese researchers ran a large-scale effort with more than 100 children. Early signals showed about 60% of those with gastrointestinal complaints gained major relief in sleep, bowels, behavior and language.
Industry insiders watch the next phase closely. Double-blind, placebo-controlled studies with hundreds of participants will decide whether this moves from promising signal to standard option. Delivery methods vary. Capsules, enemas, colonoscopy. Each carries different burdens for children already sensitive to medical procedures. Donor screening standards must tighten further to avoid transferring unwanted microbes or viruses. Long-term safety data beyond two years stays thin.
Still the numbers tempt. A nearly 50% drop in core symptoms that holds for years would change lives. Reduced repetitive behaviors. Better communication. Fewer tantrums. Improved sleep and digestion. Parents report these shifts in follow-up surveys. Clinicians see them on standardized scales. The microbiome changes appear durable. Diversity climbs and stays higher. Certain species colonize and persist.
But enthusiasm needs tempering. Not every child responds the same. Those with severe gastrointestinal symptoms sometimes gain less on social scales than those without. Placebo effects run high when families invest time and hope in novel therapies. Larger trials must isolate the transplant’s true contribution. They must track developmental trajectories against matched controls who receive only behavioral therapy or standard care.
So far the data paint an encouraging picture. Open studies from Arizona, Japan and elsewhere line up on symptom relief. Microbial shifts track with clinical gains. The gut-brain axis looks real enough to justify serious investment in confirmatory research. Regulators, payers and clinicians will demand those phase 3 numbers before broad adoption. Families cannot wait forever. Some already seek treatment outside trials despite the experimental label.
The field sits at a crossroads. Rigorous science could confirm a new avenue for easing autism’s burdens. Or it could reveal that early excitement overstated the case. Either outcome sharpens understanding of how the intestine talks to the developing brain. For now researchers press ahead with bigger, better-controlled work. The children deserve answers built on solid ground.
WebProNews is an iEntry Publication